- Home
- HUMA vs QNCX Comparison
HUMA vs QNCX Comparison
Compare HUMA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | QNCX |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 167.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HUMA | QNCX |
|---|---|---|
| Price | $1.07 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $10.00 | $7.67 |
| AVG Volume (30 Days) | ★ 5.4M | 979.1K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,571,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $731.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.72 |
| 52 Week High | $4.85 | $4.55 |
Technical Indicators
Market Signals| Indicator | HUMA | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 47.31 |
| Support Level | $0.96 | $2.85 |
| Resistance Level | $1.15 | $3.72 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 33.20 | 41.38 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.